Search academic texts

Registration Number

0225U001203, (0124U000651) , R & D reports

Title

To develop an optimal algorithm for complex treatment of resistant breast cancer

popup.stage_title

Визначити популяцію хворих на рак грудної залози з високим ризиком резистентності до лікування та дослідити можливості інтенсифікації лікування резистентного раку грудної залози.

Head

Smolanka Ivan I., д.мед.н.

Registration Date

27-01-2025

Organization

National Cancer Institute

popup.description1

To identify a group of breast cancer patients with a risk of chemoresistance. To compare the effectiveness of treatment of patients with resistant breast cancer using the developed methods with traditional treatment. To develop an algorithm for the treatment of patients with resistant breast cancer.

popup.description2

The object of the study is resistant breast cancer after two consecutive lines of polychemotherapy. The purpose of the study is to identify a group of breast cancer patients at risk of chemoresistance. To compare the effectiveness of treatment of patients with resistant breast cancer using the developed methods with traditional treatment. To develop an algorithm for treating patients with resistant breast cancer. Research methods and equipment are clinical, morphological, radiological, statistical; Siemens mammograph, Aloka ultrasound device, Philips BV Pulsera angiographic device, Magnitherm device. The immediate results of treatment of patients with resistant breast cancer using standard and developed methods of neoadjuvant polychemotherapy with magnetothermy were analyzed. A comparative analysis of intermediate results indicates a significant advantage of methods with the addition of magnetothermy compared to standard systemic polychemotherapy. Also, the advantage of pegylated chemotherapy methods compared to dose-dence chemotherapy methods was determined. At the reporting time, neoadjuvant treatment was fully performed in 36 patients (9 in each group). No cases of progression of the process were observed in any of the groups. Stabilization of the process was noted in 8 patients in the dosedence chemotherapy group, 7 patients in the dosedence chemotherapy with magnetothermy group, 3 patients in the pegylated chemotherapy group and 2 patients in the combination of pegylated chemotherapy with magnetothermy group. The best results of achieving a response (partial + complete regression) were obtained in the combination of pegylated chemotherapy with magnetothermy group (7 patients) and pegylated drugs (6 patients). While in the dosedence-chemotherapy with magnetothermy group, 2 patients responded to treatment (partial+complete regression), and in the dosedence-chemotherapy group, 1 patient responded.

Product Description

popup.authors

Ivankova Oksana M.
Dosenko Iryna V.
Loboda Anton D.
Liashenko Andrii O.
Movchan Oleksii V.

popup.nrat_date

2025-01-27